Aliases & Classifications for Fainting

MalaCards integrated aliases for Fainting:

Name: Fainting 54 43

Summaries for Fainting

NINDS : 54 Syncope is a medical term used to describe a temporary loss of consciousness due to the sudden decline of blood flow to the brain. Syncope is commonly called fainting or “passing out.” If an individual is about to faint, he or she will feel dizzy, lightheaded, or nauseous and their field of vision may “white out” or “black out.”  The skin may be cold and clammy.  The person drops to the floor as he or she loses consciousness.  After fainting, an individual may be unconscious for a minute or two, but will revive and slowly return to normal.  Syncope can occur in otherwise healthy people and affects all age groups, but occurs more often in the elderly.  There are several types of syncope.  Vasovagal syncope usually has an easily identified triggering event such as emotional stress, trauma, pain, the sight of blood, or prolonged standing.  Carotid sinus syncope happens because of constriction of the carotid artery in the neck and can occur after turning the head, while shaving, or when wearing a tight collar.  Situational syncope happens during urination, defecation, coughing, or as a result of gastrointestinal stimulation.  Syncope can also be a symptom of heart disease or abnormalities that create an uneven heart rate or rhythm that temporarily affect blood volume and its distribution in the body.  Syncope isn’t normally a primary sign of a neurological disorder, but it may indicate an increased risk for neurologic disorders such as Parkinson’s disease, postural orthostatic tachycardia syndrome (POTS), diabetic neuropathy, and other types of neuropathy.  Certain classes of drugs are associated with an increased risk of syncope, including diuretics, calcium antagonists, ACE inhibitors, nitrates, antipsychotics, antihistamines, levodopa, narcotics, and alcohol.

MalaCards based summary : Fainting is related to ventricular fibrillation, paroxysmal familial, 1 and cerebral arteritis. An important gene associated with Fainting is KCNH2 (Potassium Voltage-Gated Channel Subfamily H Member 2), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Complement and coagulation cascades. The drugs Propranolol and Fludrocortisone have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and skin.

MedlinePlus : 43 Fainting is a temporary loss of consciousness. If you're about to faint, you'll feel dizzy, lightheaded, or nauseous. Your field of vision may "white out" or "black out." Your skin may be cold and clammy. You lose muscle control at the same time, and may fall down. Fainting usually happens when your blood pressure drops suddenly, causing a decrease in blood flow to your brain. It is more common in older people. Some causes of fainting include Heat or dehydration Emotional distress Standing up too quickly Certain medicines Drop in blood sugar Heart problems When someone faints, make sure that the airway is clear and check for breathing. The person should stay lying down for 10-15 minutes. Most people recover completely. Fainting is usually nothing to worry about, but it can sometimes be a sign of a serious problem. If you faint, it's important to see your health care provider and find out why it happened.

Wikipedia : 75 Syncope, also known as fainting, is a loss of consciousness and muscle strength characterized by a fast... more...

Related Diseases for Fainting

Graphical network of the top 20 diseases related to Fainting:



Diseases related to Fainting

Symptoms & Phenotypes for Fainting

Drugs & Therapeutics for Fainting

Drugs for Fainting (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propranolol Approved, Investigational Phase 4 525-66-6 4946
2
Fludrocortisone Approved, Investigational Phase 4 127-31-1 31378
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Sodium citrate Approved, Investigational Phase 4 68-04-2
5
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
6
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
7
Linagliptin Approved Phase 4 668270-12-0 10096344
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Empagliflozin Approved Phase 4 864070-44-0
10
Canagliflozin Approved Phase 4 842133-18-0
11
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
12
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
13
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
14 Anesthetics, Intravenous Phase 4
15 Citrate Phase 4
16 Narcotics Phase 4
17 Adjuvants, Anesthesia Phase 4
18 Analgesics, Opioid Phase 4
19 Anesthetics, General Phase 4
20 Neurotransmitter Agents Phase 4
21 Adrenergic beta-Antagonists Phase 4
22 Adrenergic Antagonists Phase 4
23 Adrenergic Agents Phase 4
24 Anti-Arrhythmia Agents Phase 4
25 Peripheral Nervous System Agents Phase 4
26 Autonomic Agents Phase 4
27 Sodium Channel Blockers Phase 4
28 Diuretics, Potassium Sparing Phase 4
29 Adrenergic beta-1 Receptor Antagonists Phase 4
30 Sympatholytics Phase 4
31 Anti-Obesity Agents Phase 4
32 HIV Protease Inhibitors Phase 4
33 Sitagliptin Phosphate Phase 4
34 Sodium-Glucose Transporter 2 Inhibitors Phase 4
35 Lipid Regulating Agents Phase 4
36
protease inhibitors Phase 4
37 Dipeptidyl-Peptidase IV Inhibitors Phase 4
38 Incretins Phase 4
39 Hypoglycemic Agents Phase 4
40 Hormone Antagonists Phase 4
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
42 Sympathomimetics Phase 4
43 Vasoconstrictor Agents Phase 4
44
Norepinephrine Approved Phase 3 51-41-2 439260
45
Parathyroid hormone Approved, Investigational Phase 3 9002-64-6
46
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
47 Calcium, Dietary Phase 3
48
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
49
Ethanol Approved Phase 2 64-17-5 702
50
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 Syncope: Pacing or Recording in the Later Years (SPRITELY) Completed NCT01423994 Phase 4
2 A Randomized Clinical Trial of Fludrocortisone for Vasovagal Syncope: The Second Prevention of Syncope Trial (POST II) Completed NCT00118482 Phase 4 fludrocortisone acetate
3 Fish Oil for Atrial Fibrillation - Effect and Mechanisms Completed NCT00552084 Phase 4 Fish oil;Placebo
4 Propranolol for Syncope With Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
5 A Prospective, Randomized, Double Blind Study Comparing the Efficacy and Safety of Fentanyl Nasal Spray to Placebo as an Analgesic, in Patients Undergoing Outpatient Cystoscopic Procedures Completed NCT01708122 Phase 4 Fentanyl;saline
6 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
7 Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes vs Best Medical Treatment Recruiting NCT02041234 Phase 4 Incretin analogues;Xenical;SGLT2 inhibitors;DPP-4 Inhibitors
8 Effects of Perampanel on Neurophysiology Test Perimeters Recruiting NCT03653741 Phase 4 Perampanel 6 MG
9 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
10 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV (Post 4) Active, not recruiting NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
11 Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrillation and Flutter Completed NCT01439386 Phase 3
12 A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure Recruiting NCT03829657 Phase 3 ampreloxetine;Placebo
13 A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure Recruiting NCT03750552 Phase 3 ampreloxetine;Placebo
14 Effects of PTH Replacement on Bone in Hypoparathyroidism Terminated NCT00395538 Phase 3 PTH 1-34
15 Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After ESWL Withdrawn NCT01560091 Phase 3 silodosin;Tamsulosin
16 Long-term, Open Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of QCC374 in Patients With Pulmonary Arterial Hypertension (PAH) Completed NCT02939599 Phase 2 QCC374
17 Propranolol for Syncope With Sympathoadrenal Imbalance in Children Completed NCT00093860 Phase 2 Propranolol
18 Preventing Adverse Reactions in Novice Blood Donors Completed NCT00302900 Phase 2
19 A Randomized Prospective Comparison of DDD Chamber Pacing and Percutaneous Transluminal Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Associated With Severe Drug-Refractory Symptoms Completed NCT00001894 Phase 2
20 Glutathione (GSH) In The Treatment of Parkinson's Disease Completed NCT01177319 Phase 2 Glutathione
21 A Pilot Study: Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas Completed NCT00624416 Phase 1, Phase 2 Prednisolone synthetic cortisone and Isoproterenol together
22 Trans-Right Ventricular Approach to Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Feasibility Study Completed NCT00035386 Phase 2
23 Controlled Cross-Over Study of DDD Pacemaker Therapy in Symptomatic Children With Obstructive Hypertrophic Cardiomyopathy Completed NCT00001960 Phase 2
24 A Proof of Principal Study of Atomoxetine for the Prevention of Vasovagal Syncope (POST 6) Completed NCT02874937 Phase 2 Atomoxetine;Matching Placebo
25 The Effects of ARA290 on the Cognitive and Neural Processing of Emotions in Healthy Volunteers Completed NCT02070783 Phase 1, Phase 2 ARA290;Placebo
26 Methionine-Restriction Diet (MRD) in Obese Adults With Metabolic Syndrome Completed NCT00640757 Phase 2
27 Evaluation of the Safety and Efficacy of a Standardized Eucommia Extract in the Treatment of Hypertension Completed NCT00626132 Phase 2
28 The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Pulmonary Hypertension: Initial Studies for Establishing Guidelines Completed NCT00678821 Phase 2
29 Safety and Efficacy of Intravenous Norepinephrine for Orthostatic Hypotension Completed NCT01285908 Phase 1, Phase 2 Intravenous Norepinephrine Infusion
30 Non-Pharmacologic Therapy for Neurocardiogenic Syncope Completed NCT00096902 Phase 2
31 A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope (VVS): POST 6 Completed NCT02500732 Phase 2 Atomoxetine;Placebo
32 Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High Risk Melanoma Completed NCT00273910 Phase 2 gp100:209-217 (210M);Montanide ISA-51;Imiquimod
33 A Double-blind Randomized Placebo-controlled Study of Aspirin and N-acetyl Cysteine as Adjunctive Treatments for Bipolar Disorder Patients (SMRI 11T-009) Completed NCT01797575 Phase 2 Aspirin;Sugar Pill
34 Study of the Effect of Naltrexone on Cerebral Blood Flow and Hypoglycemia in Type 1 Diabetes Mellitus Completed NCT01053078 Phase 1, Phase 2 Naltrexone;Naltrexone
35 Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Recruiting NCT02558972 Phase 2 Northera (Droxidopa);Placebo;Northera (Droxidopa);Placebo
36 Microbiota-directed Complementary Food (MDCF) Trial Recruiting NCT04015999 Phase 2
37 Microbiota Directed Complementary Food (MDCF) Post-SAM MAM Trial Recruiting NCT04015986 Phase 2
38 A Randomized, Parallel-group, Placebo-controlled Subject and Investigator Blinded Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of QCC374 in the Treatment of Pulmonary Arterial Hypertension Terminated NCT02927366 Phase 2 QCC374;Placebo Matching
39 Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement Withdrawn NCT02365415 Phase 2 Sirolimus
40 A Phase 1 Dose Escalating Study of Double Mutant Heat-Labile Toxin LTR192G/L211A (dmLT) From Enterotoxigenic Escherichia Coli (ETEC) by Sublingual or Oral Immunization to Determine Safety and Immunogenicity of a Multi-dose Regimen in Adult Humans Completed NCT02052934 Phase 1
41 A Human Pilot Study to Quantify BCG From the BCG Vaccination Site, and to More Fully Characterise the Immune Response to BCG Completed NCT00653627 Phase 1
42 Reducing Orthostatic Intolerance With Oral Rehydration in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Active, not recruiting NCT02854683 Phase 1 Normal Saline
43 EXercise for the Prevention of Syncope Evaluation Suspended NCT00203593 Phase 1
44 Observational Study of the Sleuth Implantable ECG Monitoring System Unknown status NCT00717106
45 Randomized Trial of Cardiovascular Response to Two Manual Techniques Non-thrust Joint Manipulation of the Cervical Spine in Patients With Non-traumatic Mechanical Neck Pain. Unknown status NCT02198677
46 Assessment of Adverse Cardiac Events Using Local Anesthesia With Adrenaline Unknown status NCT02738567
47 Stone Centre Urine and Serum Bank Unknown status NCT00759343
48 Cohort Description of Younger With AV-block Unknown status NCT03024047
49 A Lifestyle Intervention to Improve in Vitro Fertilization Results Unknown status NCT02648555
50 The GlasVEGAS Study (Glasgow Visceral & Ectopic Fat With Weight Gain in South AsianS) - Does Adipose Tissue Expandibility Differ Between South Asians and Europeans and Does This Contribute to Differences in Cardio-metabolic Disease Risk? Unknown status NCT02399423

Search NIH Clinical Center for Fainting

Genetic Tests for Fainting

Anatomical Context for Fainting

MalaCards organs/tissues related to Fainting:

41
Heart, Brain, Skin, Testes, Kidney, Bone, Whole Blood

Publications for Fainting

Articles related to Fainting:

(show top 50) (show all 1100)
# Title Authors PMID Year
1
When Is Syncope Arrhythmic? 17
31378326 2019
2
Did This Patient Have Cardiac Syncope?: The Rational Clinical Examination Systematic Review. 17
31237649 2019
3
Bearing Witness and Finding Meaning. 17
30874759 2019
4
Blood and organ donation: health impact, prevalence, correlates, and interventions. 38
31213077 2019
5
Mechanisms of tilt-induced vasovagal syncope in healthy volunteers and postural tachycardia syndrome patients without past history of syncope. 38
31250563 2019
6
Deep Infiltrating Endometriosis and Spontaneous Hemoperitoneum: A Life-Threatening Situation Treated by Laparoscopy. 38
31376586 2019
7
Efficacy and safety of acupuncture as an adjuvant treatment for acute pancreatitis: a protocol of systematic review and meta-analysis. 38
31278104 2019
8
Expansion of the Primrose syndrome phenotype through the comparative analysis of two new case reports with ZBTB20 variants. 38
31321892 2019
9
Late Survival and Patient-Perceived Health Status of the CHSS dextro-Transposition of the Great Arteries Cohort. 38
31348901 2019
10
Prehospital clinical presentation in patients with acute coronary syndrome complicated by cardiogenic shock: A single center study. 38
30213588 2019
11
[Facial redness and fainting after elevation of both arms in a 74 year-old man]. 38
31103242 2019
12
Quality of life improves in vasovagal syncope patients after clinical trial enrollment regardless of fainting in follow-up. 38
31122600 2019
13
Predonation fears identify young donors at risk for vasovagal reactions. 38
31267576 2019
14
Estimating the risk of blood donation fainting for self versus others: the moderating effect of fear. 38
30828820 2019
15
Atypical Prodromal Symptoms Help to Distinguish Patients With Psychogenic Nonsyncopal Collapse Among Youth Referred for Fainting. 38
30922770 2019
16
[New Targets in Blood Pressure Control: Arguments Pro and Contra]. 38
31131773 2019
17
Childhood poly-victimization and children's health: A nationally representative study. 38
30852428 2019
18
Involving stakeholders in informing the development of a Knowledge Translation (KT) intervention to improve the vaccination experience at school. 38
30948919 2019
19
Stakeholder feedback on The CARD™ System to improve the vaccination experience at school. 38
30948920 2019
20
Overview of a Knowledge Translation (KT) Project to improve the vaccination experience at school: The CARD™ System. 38
30948918 2019
21
Piloting The CARD™ System for education of students about vaccination: Does it improve the vaccination experience at school? 38
30948921 2019
22
[Effects on urinary retention after spinal cord injury treated with acupuncture at Zhibian (BL 54) and Shuidao (ST 28) with elongated needle]. 38
30957445 2019
23
The Fainting Assessment Inventory: A 10-Item Instrument Developed to Screen for Psychogenic Nonsyncopal Collapse Among Youth Referred for Syncope. 38
30921250 2019
24
Intermittent calf compression reverses lower limb pooling and improves cardiovascular control during passive orthostasis. 38
30638840 2019
25
Putting the Spirit into Culturally Responsive Public Health: Explaining Mass Fainting in Cambodia. 38
29956053 2019
26
Fear of blood, injections and fainting as barriers to blood donation in Brazil. 38
30485453 2019
27
[Follow-up of Patients with Cardiac Pacemakers]. 38
30890083 2019
28
Effects of Breath-Hold Deep Diving on the Pulmonary System. 38
30783070 2019
29
Are the health needs of children with disabilities being met at primary schools? 38
30621499 2019
30
HPV vaccine confidence and cases of mass psychogenic illness following immunization in Carmen de Bolivar, Colombia. 38
30118381 2019
31
Abdominal Pregnancy: A Case Report of a Viable Nondysmorphic Fetus. 38
31413435 2019
32
Collapse in the scrum. 38
29507049 2018
33
Sleep Fainting: A Neurocardiogenic Entity. 38
30820371 2018
34
Ammonia Inhalation Does Not Increase Deadlift 1-Repetition Maximum in College-Aged Male and Female Weight Lifters. 38
30480652 2018
35
Autonomic dysfunction and HPV immunization: an overview. 38
30478703 2018
36
Review of the Evaluation and Treatment of Vasovagal Reactions in Outpatient Procedures. 38
29994949 2018
37
TA pharmacopuncture as a primary and independent treatment for frequent sprains occurring over 9 months in a patient with needle sickness: Case report. 38
30407331 2018
38
Acute-on-chronic subdural hematoma: the death of the famous XIX century soprano Maria Malibran-a study of the sources. 38
29987434 2018
39
Fear of blood draw is associated with inflated expectations of faint and prefaint reactions to blood donation. 38
30222871 2018
40
Signs of autonomic arousal precede tilt-induced psychogenic nonsyncopal collapse among youth. 38
30055943 2018
41
The Medicalization of Poverty in the Lives of Low-Income Black Mothers and Children. 38
30336076 2018
42
Early outcomes in youth with psychogenic nonsyncopal collapse. 38
30045963 2018
43
[Key Points of the 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope]. 38
30131047 2018
44
Low level of knowledge of heart attack symptoms and inappropriate anticipated treatment-seeking behaviour among older Chinese: a cross-sectional survey. 38
29581229 2018
45
[Management of hypertrophic cardiomyopathy - the most common inherited heart disease]. 38
29893985 2018
46
[Syncope due to giant goitre]. 38
29886887 2018
47
Feasibility of a pilot intervention to reduce pain and syncope during adolescent vaccination. 38
29805090 2018
48
[Differential Diagnostics of Vasovagal Fainting, Orthostatic Hypotension and Baroreflex Failure in a Patient With Syncope]. 38
29870329 2018
49
The pre-participation screening in young athletes: which protocol do we need exactly? 38
29183415 2018
50
Prepare for Take-Off: Fasten Your Seatbelt and Keep a Magnet in Your Pocket! 38
29262873 2018

Variations for Fainting

Expression for Fainting

Search GEO for disease gene expression data for Fainting.

Pathways for Fainting

GO Terms for Fainting

Cellular components related to Fainting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.62 VWF F8

Biological processes related to Fainting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.32 VWF F8
2 platelet degranulation GO:0002576 9.26 VWF F8
3 platelet activation GO:0030168 9.16 VWF F8
4 hemostasis GO:0007599 8.96 VWF F8
5 blood coagulation, intrinsic pathway GO:0007597 8.62 VWF F8

Sources for Fainting

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....